Medtronic Plc stock
MDTNYSEHealthcareISIN IE00BTN1Y115
70Score 70 out of 100, Strong
Price and trend
84 / 100
Price history
+5.4% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 4.1% below its 52-week high. Largest decline in 20 years: 58% (October 2007 to March 2009).
Chart figures for advanced users
- SMA 50$93.53
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$88.25
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$73.75
- The lowest closing price of the last twelve months.
- Resistance$105.35
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Medtronic Plc belongs to the Medical (Devices) industry (Ireland) and, with a market value of $129.18B, is number 2 of 88 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $36.36B (up 8.4% year on year) and earnings of $4.8B (up 3%).
- For fiscal 2027, analysts expect on average revenue of $39.05B (up 7.4%) and adjusted earnings per share of $5.98 (up 8.1%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 141 of 702 in Healthcare, median 53.
- The P/E is 24.8 (Medical (Devices) median 29.1, own median of recent years 28.1).
- Our model puts fair value at $104.26, with the price 3% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 44 years.Capital allocation 62
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 84
- Earnings turn into cashFree cash flow 117% of earnings over the last 12 months.Fundamentals 84
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and technical analysis.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $80.20 and expensive above $148.94 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $90.25 (cash-flow model) and $118.27 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $97.55, at 8.9% it would be $113.66.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Jul 2026, revenue rose 9.8% on the twelve months before. Revenue has grown solidly since 2007, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 65%, operating 18%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Nov 2026in 11 days
- Last reported
- 1 Sep 2026EPS reported $1.45 (expected $1.39)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.980.0%
- Revenue
- $39.05B0.0%
- Earnings per share
- $6.39−0.1%
- Revenue
- $40.28B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +1.7%Fiscal 2027 organic revenue growth guidance was raised by 50 basis points to 7.25% to 7.75% and EPS guidance slightly raised to $5.94 to $6.00.
“On the top line, we are pleased with the strong performance in the first quarter, and are raising our fiscal year '27 organic revenue growth guidance to 7.25% to 7.75%, which represents a 50 basis points increase from our prior guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 1 Sep 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $6.48M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Medtronic Plc
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Abbott LaboratoriesABT $185.75B63
- StrykerSYK $118.92B70
- Boston ScientificBSX $64.07B63
- Edwards LifesciencesEW $60.84B76
- Siemens HealthineersSHL.DE $54.32B65
- GE HealthCare TechnologiesGEHC $37B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.26B74
- DexComDXCM $30.35B79
ETFs that hold Medtronic Plc
Held by 50 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.82% | 0.15% | €3.29B |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.50% | 0.40% | €1.5B |
| iShares Inclusion and Diversity UCITS ETFOPEN | 1.12% | 0.25% | €77.41M |
Show 5 more
| iShares Dow Jones Global Leaders Screened UCITS ETF USD (Acc)IUSL | 0.63% | 0.60% | €2.04B |
| iShares MSCI USA Quality Dividend Advanced UCITS ETFQDVD | 0.57% | 0.35% | €794.64M |
| iShares MSCI World Value Factor Advanced UCITS ETFCBUI | 0.53% | 0.25% | €1.55B |
| iShares Edge MSCI World Value Factor UCITS ETFIS3S | 0.40% | 0.25% | €6.33B |
| iShares World Equity High Income Active UCITS ETF USDWINC | 0.37% | 0.35% | €955.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 24 Apr 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.